Emcure Pharmaceuticals Q1 FY27 reports 22.8% revenue growth to ₹25,804 million, while PAT jumps 36.2% and EBITDA rises 25.8% in Q1 FY27.
Read Moredomestic business
Emcure Pharmaceuticals Posts 63 Per Cent PAT Growth in Q4FY25
Emcure Pharmaceuticals continues to expand its presence in 70+ countries, including major global markets like Europe and Canada.
Read More